JP2017522326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522326A5 JP2017522326A5 JP2017502704A JP2017502704A JP2017522326A5 JP 2017522326 A5 JP2017522326 A5 JP 2017522326A5 JP 2017502704 A JP2017502704 A JP 2017502704A JP 2017502704 A JP2017502704 A JP 2017502704A JP 2017522326 A5 JP2017522326 A5 JP 2017522326A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- nos
- composition
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 130
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 78
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 239000013612 plasmid Substances 0.000 claims description 26
- 229920001184 polypeptide Polymers 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 26
- 206010009944 Colon cancer Diseases 0.000 claims description 15
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 13
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 239000007927 intramuscular injection Substances 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims 1
- 102100027456 Cytochrome c oxidase subunit 2 Human genes 0.000 description 21
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 21
- 101000624631 Homo sapiens M-phase inducer phosphatase 2 Proteins 0.000 description 21
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 21
- 101000830689 Homo sapiens Protein tyrosine phosphatase type IVA 3 Proteins 0.000 description 21
- 101000835900 Homo sapiens Submaxillary gland androgen-regulated protein 3B Proteins 0.000 description 21
- 102100023325 M-phase inducer phosphatase 2 Human genes 0.000 description 17
- 102100024601 Protein tyrosine phosphatase type IVA 3 Human genes 0.000 description 17
- 150000007523 nucleic acids Chemical group 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 102000009300 Fascin-1 Human genes 0.000 description 13
- 108050000138 Fascin-1 Proteins 0.000 description 13
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 13
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 13
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 13
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 13
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 13
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 101710137943 Complement control protein C3 Proteins 0.000 description 11
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 11
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 11
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 11
- 230000028993 immune response Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940031724 lung cancer vaccine Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000001855 preneoplastic effect Effects 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000031261 interleukin-10 production Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- -1 linker nucleic acids Chemical class 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462026246P | 2014-07-18 | 2014-07-18 | |
| US62/026,246 | 2014-07-18 | ||
| PCT/US2015/040960 WO2016011386A1 (en) | 2014-07-18 | 2015-07-17 | Cancer vaccine compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020196997A Division JP2021038261A (ja) | 2014-07-18 | 2020-11-27 | がんワクチン組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522326A JP2017522326A (ja) | 2017-08-10 |
| JP2017522326A5 true JP2017522326A5 (OSRAM) | 2018-09-20 |
| JP6820830B2 JP6820830B2 (ja) | 2021-01-27 |
Family
ID=55079097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502704A Active JP6820830B2 (ja) | 2014-07-18 | 2015-07-17 | がんワクチン組成物およびその使用方法 |
| JP2020196997A Withdrawn JP2021038261A (ja) | 2014-07-18 | 2020-11-27 | がんワクチン組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020196997A Withdrawn JP2021038261A (ja) | 2014-07-18 | 2020-11-27 | がんワクチン組成物およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10759836B2 (OSRAM) |
| EP (1) | EP3169699A4 (OSRAM) |
| JP (2) | JP6820830B2 (OSRAM) |
| CN (1) | CN106715458A (OSRAM) |
| WO (1) | WO2016011386A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6820830B2 (ja) | 2014-07-18 | 2021-01-27 | ユニヴァーシティ オブ ワシントン | がんワクチン組成物およびその使用方法 |
| CA3026172A1 (en) | 2016-06-02 | 2017-12-07 | Ultimovacs As | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| CN110709094A (zh) | 2017-02-03 | 2020-01-17 | 威斯康星州医药大学股份有限公司 | Kras肽疫苗组合物及其使用方法 |
| WO2020193628A1 (en) * | 2019-03-25 | 2020-10-01 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Enhancement of cytolytic t-cell activity by inhibiting ebag9 |
| WO2024196664A1 (en) * | 2023-03-17 | 2024-09-26 | University Of Washington | Dna vaccine targeting overexpressed antigens in colorectal cancer |
| CN118879783B (zh) * | 2024-07-04 | 2025-08-08 | 恒敬合创生物医药（浙江）有限公司 | 一种用于包裹核酸药物的环状脂肽载体 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520A (en) | 1848-04-18 | Oegan-pipb | ||
| US639A (en) | 1838-03-17 | of boston | ||
| US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US5190029A (en) | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5294538A (en) | 1991-11-18 | 1994-03-15 | Cold Spring Harbor Labs. | Method of screening for antimitotic compounds using the CDC25 tyrosine phosphatase |
| CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
| US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| US5376359A (en) | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| WO1994015635A1 (en) | 1993-01-11 | 1994-07-21 | Dana-Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| PT681483E (pt) | 1993-01-26 | 2005-11-30 | Wyeth Corp | Composicoes e metodos para distribuicao de material genetico |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| CA2284586C (en) | 1997-04-01 | 2011-02-08 | Ribi Immunochem Research, Inc. | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| JP2007527503A (ja) * | 2003-06-17 | 2007-09-27 | プロノタ・エヌブイ | ペプチドコンボ及びそれらの使用 |
| ATE546153T1 (de) * | 2003-06-17 | 2012-03-15 | Mannkind Corp | Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen |
| US20080171058A1 (en) | 2003-11-13 | 2008-07-17 | Polly Gregor | Compositions and Methods For Synergistic Induction of Antitumor Immunity |
| US20070243215A1 (en) | 2004-10-08 | 2007-10-18 | Miller Richard L | Adjuvant for Dna Vaccines |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| US9060961B2 (en) * | 2006-11-09 | 2015-06-23 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| WO2011004263A2 (en) * | 2009-07-07 | 2011-01-13 | Novartis Ag | Conserved escherichia coli immunogens |
| GB201003333D0 (en) * | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| EP2832363B1 (en) * | 2012-03-27 | 2018-09-19 | Green Cross Corporation | Epitopes of epidermal growth factor receptor surface antigen and use thereof |
| JP6820830B2 (ja) | 2014-07-18 | 2021-01-27 | ユニヴァーシティ オブ ワシントン | がんワクチン組成物およびその使用方法 |
-
2015
- 2015-07-17 JP JP2017502704A patent/JP6820830B2/ja active Active
- 2015-07-17 EP EP15822502.9A patent/EP3169699A4/en not_active Withdrawn
- 2015-07-17 CN CN201580050431.1A patent/CN106715458A/zh active Pending
- 2015-07-17 US US15/327,225 patent/US10759836B2/en active Active
- 2015-07-17 WO PCT/US2015/040960 patent/WO2016011386A1/en not_active Ceased
-
2020
- 2020-11-27 JP JP2020196997A patent/JP2021038261A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522326A5 (OSRAM) | ||
| JP2016128513A5 (OSRAM) | ||
| JP2017513502A5 (OSRAM) | ||
| IL276210B2 (en) | Mers-cov vaccine | |
| JP2020528911A5 (OSRAM) | ||
| RU2014144133A (ru) | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2015524794A5 (OSRAM) | ||
| JP2016505635A5 (OSRAM) | ||
| RU2016145464A (ru) | Рекомбинантные вакцинные штаммы listeria и способы их получения | |
| JPH10509448A (ja) | 生の組換え細菌ワクチンベクターを用いる癌の特異的免疫療法 | |
| JP2016136950A5 (OSRAM) | ||
| JP2015506179A5 (OSRAM) | ||
| JP2016513115A5 (OSRAM) | ||
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| JP2019508403A5 (OSRAM) | ||
| MX2022005704A (es) | Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b. | |
| AU2017264901A1 (en) | Combination prime: boost therapy | |
| JP2019505567A5 (OSRAM) | ||
| JP2014519817A5 (OSRAM) | ||
| JP2017516462A5 (OSRAM) | ||
| JP2013545448A5 (OSRAM) | ||
| JP2019527676A5 (OSRAM) | ||
| Namkoong et al. | Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11 | |
| JP2018509423A5 (OSRAM) |